H
HepaTx
5/10Traction
Develops off-the-shelf cell therapies using stem cell-based regenerative medicine to treat late-stage liver disease, providing a scalable alternative to liver transplantation. This approach addresses the critical shortage of donor organs, with over 200,000 patients annually facing end-stage liver failure in the U.S. alone.
- Biotechnology
Updated 22 months ago
Funding
Raised to date
$2.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Intbox VenturesNo round attributed
- intboxventures.com (opens in a new tab)investor website
Linden3No round attributed
- linden3.com (opens in a new tab)investor website
Y CombinatorNo round attributed
- Source unavailable
Funding rounds are not available yet.
Founders
Product
Features
- Develops off-the-shelf cell therapies using stem cell-based regenerative medicine to treat late-stage liver disease, providing a scalable alternative to liver transplantation. This approach addresses the critical shortage of donor organs, with over 200,000 patients annually facing end-stage liver failure in the U.S. alone.